Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus QUINATIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus QUINATIME.
CIN-QUIN vs QUINATIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)